Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | EPHX1 | P07099 | 4/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24673291 | 0.91 | — | — | |
| SCHEMBL20322090 | 0.83 | EPHX1 (0.47) | EPHX1 | |
| SCHEMBL19057654 | 0.81 | EPHX1 (0.50) | EPHX1 | |
| SCHEMBL25881306 | 0.81 | EPHX1 (0.50) | EPHX1 | |
| SCHEMBL22861925 | 0.81 | EPHX1 (0.50) | EPHX1 | |
| SCHEMBL25697792 | 0.81 | EPHX1 (0.50) | EPHX1 | |
| SCHEMBL19200596 | 0.80 | EPHX1 (0.41) | MEN1KMT2AEPHX1 | |
| SCHEMBL24673609 | 0.79 | MEN1 (0.37) | MEN1KMT2AEPHX1 | |
| SCHEMBL12061986 | 0.78 | EPHX1 (0.50) | MEN1KMT2AEPHX1 | |
| SCHEMBL23451083 | 0.78 | EPHX1 (0.38) | MEN1KMT2AEPHX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230190940-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-06-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230190940-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | MEN1 4055/4885KMT2A 445/4885EPHX1 1684/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.